BEIJING — Here are the latest developments on the novel coronavirus disease (COVID-19) in China:

— Vice-Premier Sun Chunlan on April 20 told medical experts in Wuhan in the central Chinese province of Hubei to make all-out efforts to save and treat every COVID-19 patient.

— China has strengthened border control measures for the containment of imported novel coronavirus disease (COVID-19) risk.

— China will step up epidemic prevention and control measures in major cities and at key ports, resolutely guarding against the cross-border spread of coronavirus.

— Guangzhou, the capital city of South China's Guangdong province will expand the scope of nucleic acid tests to cope with the heavy tasks of preventing the novel coronavirus epidemic from rebounding.

Guangzhou has issued a multilingual open letter, urging joint efforts against COVID-19 and appealing zero tolerance over discriminatory language or acts.

— Shanghai will restart classes for non-senior students by stage from May 6, local authorities said on April 20, after announcing earlier this month that senior students in middle and high schools will resume classes from April 27.

— An epidemic prevention and control work team departed on April 20 for Kyrgyzstan from Northwest China's Xinjiang Uygur autonomous region to join the battle against the COVID-19 pandemic.

— Central China's Hubei province, which was hit hard by COVID-19, announced on April 20 that the province's national college entrance exam, also known as Gaokao, would be postponed by one month to July 7 and 8.

— Chinese health authority said on April 20 that it received reports of 12 new confirmed COVID-19 cases on the mainland Sunday, of which eight were imported.

The other four new cases were domestically transmitted, the National Health Commission said in a daily report, noting that three cases were reported in Heilongjiang Province and one in Inner Mongolia autonomous region.

No death was reported on April 19 on the mainland. Two new suspected cases, all imported ones in Shanghai, were also reported.

— A total of 22 patients of the novel coronavirus disease (COVID-19) were discharged from hospitals on April 19 on the Chinese mainland, according to the National Health Commission.

Altogether 77,084 patients had been discharged from hospitals after recovery by the end of April 19, the commission said in its daily report on April 20.

As of April 19, 82,747 confirmed COVID-19 cases had been reported on the mainland, and 4,632 people had died of the disease.

— The Chinese mainland reported eight new imported cases of the novel coronavirus disease (COVID-19) April 19, bringing the total number of imported cases to 1,583, the National Health Commission said on April 20.

The mainland also reported two new suspected cases on April 19, all imported ones, the commission said in its daily report.

Of the total imported cases, 742 had been discharged from hospitals after recovery, and 841 were being treated in hospitals with 43 in severe condition, the commission said.

No deaths had been reported from the imported cases.

— A new study suggested that the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) among hospitalized COVID-19 patients with hypertension was associated with lower risk of all-cause mortality compared to nonusers.

Led by Li Hongliang, dean of the School of Basic Medical Sciences at Wuhan University, the team consisted of researchers from nine hospitals in Central China's Hubei province as well as researchers from the United States, Britain and Canada.

— An online trade fair assembling 100 medical supply manufacturers in East China's Zhejiang province and more than 80 Italian medical institutions, multinational firms and business associations was launched on April 17.

Scheduled to conclude on April 22, the fair is expected to help meet the urgent demand for anti-epidemic supplies in Italy.

It will also hold two targeted procurement sessions for Italian private businesses and for an Italian hospital respectively.